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SUMMARY
According to the Centre for Disease Prevention and Control of Latvia data, in 2014 16076 latvians died from cardiovascular diseases 
and it is 57,03% of all deaths. Changes in myocardium of the diseased hearts are complex and pathogenesis is still not fully 
clear. Morphopathogenesis of cardiovascular diseases are complex molecular cell changes  which include apoptosis, homeostasis 
regulating factors, and innervation and ischemia markers. 
In this article we wanted to  provide an overview about apoptosis, atrial natriuretic peptide, chromogranin A, neuropeptide-containing 
innervation, endothelins and vascular endothelial growth factor in pathomorphology of acquired heart diseases and their clinical 
implications.
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ChgA measurement has gained interest in cardiovascular 
disease, because increased plasma concentrations are 
associated with risk of clinical deterioration and death 
with acute coronary syndromes or chronic heart failure 
(37).
Protein gene product 9.5 (PGP 9.5) is a cytoplasmic 
neuron and neuroendocrine cell-specific  protein  used 
as general marker to  visualize diffuse neuropeptide-
containing innervation (74, 97). PGP 9.5 has been 
proposed as reliable marker for visualisation of the 
cardiovascular system innervation (5).
Endothelin 1 (ET-1) is a potent vasoconstrictor and 
pro-inflammatory peptide (9). Endocardial endothelial 
cells and intramyocardial capillary endothelial cells 
are major source of ET-1 in the normal heart and 
cardiomyocytes are its primary target (67). Endothelins 
play an important role in cardiac and vascular pathology 
associated with heart failure (109).
Vascular endothelial growth factor (VEGF) is 
glycoprotein which is produced by a variety of adult 
tissues and vascular and inflammatory cells and it 
controlls vascular growth and function, vascular 
homeostasis, permeability, and vasodilatation (25, 47).
Apoptosis
Programmed cell death (apoptosis) is a regulated mode 
of cell death in multicellular organisms (42). Apoptosis 
plays a key role in maintenance of steady state in 
continously renewing tissues under both physiological 
and pathological conditions (33, 49). It is genetically 
driven and is characterized by chromatin condensation, 
nuclear shrinkage and eventual loss of nuclear 
membrane, membrane blebbing that produces apoptotic 
bodies containing cellular organelles and chromatin, 
DNA degradation into distinct nucleosomal units and 
INTRODUCTION
More than 4 million Europeans die of cardiovascular 
diseases every year despite recent decreases in mortality 
rates in many countries including Latvia where in 2012 
10 year change in mortality rate from cardiovascular 
diseases was -19% for males and -24% for females (65). 
Notwithstanding the fact, according to the Centre for 
Disease Prevention and Control of Latvia data, in 2014 
16,076 thousands latvians died from cardiovascular 
diseases and it was 57,03% of all deaths (90).
Changes in myocardium of the diseased hearts are 
complex and pathogenesis is still not fully clear. 
Morphopathogenesis of cardiovascular diseases is 
complex molecular cell changes  which include apoptosis, 
homeostasis regulating factors, and innervation and 
ischemia markers. Understanding the pathomorphology 
and its clinical implications of the cardiovascular 
diseases are important for every physician including 
cardiac surgeons, because the choice of treatment, 
surgical timing, pre and postoperative therapy depends 
on pathogenesis of the disease.
Programmed cell death (apoptosis) is a regulated mode 
of cell death in multicellular organisms (42). Apoptosis 
of cardiac muscle cells has been identified as an essential 
process in the pathogenesis and progression of heart 
failure which is a complication of other heart diseases 
(27).
Atrial natriuretic peptide (ANUP) is a cardiac hormone 
secreted mainly from atria in response to acute or 
chronic atrial stretch and is involved in fluid, electrolyte 
and vascular homeostasis (95). 
Chromogranin A (ChgA) is a glycoprotein that is stored 
and released in the extracellular environment together 
with neurotransmitters and hormones in the nervous, 
endocrine and diffuse neuroendocrine systems (36). 
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energy and protein synthesis requirement (41). The 
controlled degradation of nuclear DNA is a hallmark of 
apoptosis (41).
Programmed cell death in heart can be induced by 
several stimuli, such as hypoxia, reperfusion injury, 
tumor necrosis factor alpha, aldosterone, sodium 
nitroprusside, mechanical stretching of ventricular 
cardiomyocytes (12, 39, 50, 54, 78). Chlolesterol 
accumulation in macrophages leads to apoptosis and 
favors the  formation of the necrotic core in complex 
atherosclerotic plaques (34).  Cardiomyocyte apoptosis 
can be reduced by beta-adrenoreceptor blockers and 
inhibition of angiotensin converting enzyme (45, 48).
Apoptosis is not detected in normal adult human heart 
(101).
Apoptotic cell death is a component of myocardial 
infarction in acute myocardial infarction patients (77). 
Apoptosis  is the first and predominant form of myocyte 
cell death in recently infarcted human myocardium 
before the ischemic myocyte cell death with typical 
coagulative necrosis (101). Acute myocardial infarction 
in humans is characterized also by activation of 
programmed cell death in the surviving portion of the 
left ventricular wall (69). Apoptosis affects 5.1 - 12% 
of the myocyte population of the region bordering on 
the infarct (69, 83). Inflammatory cells that invade the 
infarct also undergo apoptosis (77). The higher rates 
of cardiomyocyte apoptosis are associated with more 
severe complications after myocardial infarction - 
earlyer clinical manifestation of heart failure, 
left ventricular systolic and diastolic dysfunction, 
ventricular dilatation and death (2,13,88). Apoptosis 
certainly is important in chronic ischemic conditions 
such as hibernating myocardium (84). Experimentally, 
apoptosis is particularly prominent during the transition 
from chronically stunned to hibernating myocardium, 
at which time there is a loss of approximetaly 30% of 
the regional myocytes (14).
Apoptosis of cardiac muscle cells has been identified as 
an essential process in the pathogenesis and progression 
to heart failure (27).  Apoptotic index in end stage 
dilated cardiomyopathy ranges from 5.0 - 35.5 (64). 
And predominantly it is observed in subendocardium or 
subepicardium (64).
Atrial Natriuretic Peptide
Atrial natriuretic peptide (ANUP) is a cardiac hormone 
secreted mainly from atria and is involved in fluid, 
electrolyte and vascular homeostasis - the maintenance 
of arterial blood pressure and intravascular volume (51, 
95). ANUP is produced primarily by atrial cardiomyocyte 
and also in little amount by ventricular tissue in normal 
and failing (with either systolic or diastolic dysfunction) 
hearts and in hypertrophied ventricles (10, 11, 15, 76). 
For the first time ANUP was described by Bold et al. in 
1980, when they observed decrease in blood pressure 
and greatly increased fractional excretion of sodium and 
chloride during the infusion of atrial extract in rats (10).
Human ANUP precursor peptide gene reside on 
chromosome 1p36.2 and it`s mRNA encodes a high 
molecular wight precursor peptide proANUP which is 
proteolytically cleaved by corin, a cardiac serin protease, 
into the biologically active ANUP (15, 76).
The natriuretic peptide family comprises five principal 
peptides: atrial natriuretic peptide (ANUP), brain 
natriuretic peptide (BNP), C-type natriuretic peptide, 
urodilatin and dendroaspis natriuretic peptide (15). 
B-type natriuretic peptide is a cardiac neurohormone 
specifically secreted from the ventricles in response to 
volume expansion and pressure overload (57). C-type 
natriuretic peptide has more widespread distrubution, 
mainly in human vascular endothelial cells, lungs, 
kidneys, CNS and reproductive organs (15,68). It is 
potent endothelium-independent vasodilator, including 
coronary arteries (15, 19). Urodilatin is synthesized in 
the kidney distal tubules and interacts in a paracrine 
function with the tubular cells, and is mainly responsible 
for sodium-water homeostasis (31). Dendroaspis 
natriuretic peptide is one of the recent discovered 
ntriuretic peptides (85). It is present in healthy human 
plasma and is significantly increased in chronic heart 
failure patients (85). Similarly to ANUP and BNP, 
dendroaspis natriuretic peptide is widely distributed in 
the peripheral cytoplasm of atrial myocites and also in 
the perinuclear region (85).
ANUP is secreted from atrial granules into the 
circulation in response to acute or chronic atrial 
stretch to physiologically act as antihypertensive and 
antihypervolaemic factor (51). In adult human heart, 
chronic overload induces an increment in both ANUP 
and BNP, although it is grater in the latter, while a 
short term stimulus induces a greater increase in ANUP 
than in BNP (15, 100). ANUP is able to stimulate the 
production of cyclic guanosine monophosphate (GMP) 
(15). The physiologic actions include reducing both 
cardiac preload and afterload (decrement in peripheral 
vascular resistance)  by their natriuretic, diuretic, 
and vasodilatory actions including selective renal 
vasodilation and inhibition of renin and aldosterone 
(63, 15, 11). Reduction of cardiac pre-load is mediated 
by shifting of intravascular fluid into extravascular 
compartment, increment in venous capacitance and 
inducing of natriuresis (15).
ANUP synthesis is increased in various pathologic 
conditions, causing hemodynamic overload (95). The 
natriuretic peptides, including ANUP and BNP, are 
one of the most important counterregulatory systems 
that become activated in heart failure (58). Secretion 
of ANUP in the heart are increased in patients with 
congestive heart failure in relation to its severity (62). 
Plasma levels of ANUP are elevated also  in patients with 
chronic kidney disease, mainly because of  hypertension 
and hypervolemia  and in hyperthyroid patients 
because of stimulating by thyroxin (43, 92). In the 
ventricles of heart with hypertrophic cardiomyopathy 
and hypertensive hypertophy, the expression of ANUP 
is augmented despite the absence of heart failure (94, 
95). ANUP is found to be overexpressed in the myocytes 
surrounding myocardial lesions, such as myocardial 
infarction and myocarditis (95). In patients with cardiac 
ACTA CHIRURGICA LATVIENSIS • 2015 (15/1)
65
amyloidosis biopsy specimens from right and left 
ventricles show slightly higher immunoreactivity for 
ANUP than in the control group (95). But endocardium, 
connective tissue, vasculature and amyloid fibers are 
not immunoreactive to ANUP  in cardiac amyloidosis 
patients (95). 
Chromogranin A
Chromogranin A (ChgA) is an acid, Ca2+ binding 
glycoprotein that is stored and released in the 
extracellular environment by exocytosis together 
with neurotransmitters and hormones in the nervous, 
endocrine and diffuse neuroendocrine systems 
(36,73,16).  ChgA is a member of the granin family, witch 
includes chromogranin B and secretogranin II (99). The 
gene encoding for ChgA is located in chromosome 14 
(66). Originally chromogranin was discovered in the 
chromaffin granules of the adrenal medulla (16). 
The serum concentration of ChgA is elevated in patients 
with various neuroendocrine tumours. Elevated 
levels are strongly correlated with tumour volume 
and the highest levels are recorded in subjects with 
metastatic neuroendocrine tumours (66).  Increased 
levels of circulating ChgA also have been detected in 
postmenopausal women, heart failure, renal failure, 
hypertension, rheumatoid arthritis, sepsis, atrophic 
gastritis and in subjects treated with proton pump 
inhibitors (24, 66). This protein has long been known 
as a marker for neuroendocrine tumors, but it`s role in 
cardiovascular disease has only recently been recognized 
(8).
Heart failure is a syndrome comprising cardiac 
dysfunction and neurohumoral activation (38). In 
2007, Pieroni et al. for the first time demonstrated that 
human ventricular myocardium produces and releases 
Chg A, they showed that in the presence of dilated 
and hypertrophic cardiomyopathy, the peptide is also 
immunologically detectable on tissue sections (73, 99). 
In atrial myocytes it is co-stored with atrial natriuretic 
peptide and in the ventricle it co-localizes with brain 
natriuretic peptide (99, 104). ChgA measurement 
has gained interest in cardiovascular disease, because 
increased plasma concentrations are associated with risk 
of clinical deterioration and death in patients with acute 
coronary syndromes or chronic heart failure, even more 
-  Jansson et al. demonstrated that circulating levels 
of ChgA provide prognostic information (long term 
mortality and heart failure hospitalization) independent 
of conventional risk markers in acute coronary 
syndromes (37, 99). ChgA levels have been found to 
reflect sympathetic activity, indicating that circulating 
ChgA levels may represent overall neuroendocrine 
activity. Increased activity in the sympathetic nervous 
system is a recognized risk factor for poor outcome 
in heart failure (82). ChgA is significantly increased 
in chronic heart failure patients due to tensile stretch 
during cardiac dilatation compared to healthy controls. 
After mechanical ventricular support ChgA decreases 
only in the heart, but not in the blood (6).
ChgA acts as a prohormone giving rise several biologically 
active peptides by proteolytic cleavage operated by 
several proteases and prohormone convertases in 
secretory cells such as vasostatin (a vasodilator), 
chromacin (an anti-microbial agent), pancreastatin (a 
dsyglycemic hormone), parastatin (blocks parathyroid 
hormone release) and catestatin (a potent inhibitor 
of catecholamine release from chromaffin cells and 
adrenergic neurons and an antimicrobial agent)(8, 
24, 52, 99). The first of these peptides reported was 
pancreastatin, which inhibits glucose - stimulated 
insulin release from pancreatic beta cells and secretion 
of parathyroid hormone from the parathyroid gland 
(52).
Vasostatin is a peptide, derived from the N-terminal part 
of ChgA by serine protease (24, 66). It has been shown to 
inhibit vasoconstriction of human veins by antagonizing 
the endothelin mediated contraction of smooth 
muscle, it also can inhibit endothelial cell proliferation, 
migration and invasion induced by vascular endothelial 
growth factor (22, 52, 66).
Catestatin is a catecholine release inhibitory peptide that 
can inhibit endothelin-1 induced positive inotropism 
and coronary constriction and can induce secretion of 
potent proangiogenic factor - basic fibroblast growth 
factor (24, 99). Catestatin is preventing hypertension 
by vasodilatation, decreasing peripheral and central 
symphathetic activity and reducing cardiac contractility 
(55). Mutations in the catestatin domain of the ChgA 
gene are associated with hypertension in humans (55).
C-terminal ChgA- derived serpinin peptides are present 
in the rat heart and influence myocardial contractility 
(concentration dependent positive inotropic effect) and 
enhanced relaxation (positive lusitropy) in β-agonist-
like manner, without affecting heart rate, providing 
innovative insight into the ChgA- elicited regulation 
of cardiac function (55). Serpenin peptides may 
contribute to cardiac homeostasis by counterbalancing 
the vasostatin 1 and catestatin induced cardiosupressive 
and antiadrenergic effects (55).
Protein Gene Product 9.5
Protein gene product 9.5 (PGP 9.5) is a cytoplasmic 
neuron and neuroendocrine cell-specific  protein  used 
as a general marker to  visualize diffuse neuropeptide-
containing innervation (74, 97). PGP 9.5 was originally 
detected as a brain specific protein (97). PGP 9.5 has 
been proposed as reliable marker for visualisation of the 
cardiovascular system innervation (5).
In adult human heart there are abundant network of 
PGP 9.5 immunoreactive nerves in the walls of the 
atria, but in the ventricules relatively fewer (21, 59). 
Also in human newborns very numerous PGP 9.5 
immunoreactive nerve fascicles and fibers are found in 
both - right and left atrial tissue and slightly less, but also 
numerous, in the walls of the ventricles (21). Within 
the atrial and ventricular myocardium PGP 9.5 pozitive 
nerve fibers are forming perivascular plexi along the 
walls of the major cardiac vessels and occasionally some 
separate nerve fibers are running in close relationship 
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with myocardial cells (21, 40, 81). Nerve fiber terminals 
are identified in the atrial endocardium, epicardium and 
coronary sinus (18).
PGP 9.5 immunoreactive varicose nerve fibers, nerve 
fascicles, and nerve trunks are observed throughout 
conduction system (sinus node, atrioventricular node, 
atrioventricular bundle and ventricular branches) of 
the human heart (23). The nerve density in conduction 
system is significantly higher than in the adjacent atrial 
or ventricular myocardium (23). And the most densely 
innervated region of conduction system is sinus node, 
where PGP 9.5 immunoreactive nerve fibers and fascicles 
are distributed between nodal cells in the fibrous tissue 
matrix (23). Abundant PGP 9.5 immunoreactive nerve 
fascicles and fibers are present in the sinus node of 
human newborns and the same as in adults - positively 
staining nerve fascicles and fibers are also seen among 
the cells of the atrioventricular node, bundle of His, and 
the branching bundle, the density of fibers being slightly 
less than in sinus node (22).
There are rich neworks of nerves immunoreactive 
to PGP 9.5 in cusps of atrioventricular – mitral and 
tricuspid valves and in chordae tendineae (5). The nerve 
fibres ramifies from the ventricles through the papillary 
muscles into the chordae tendineae and than passe up 
through the chordae to terminate in the valve cusp (5). 
The nerves of the terminal innervation network of the 
atrioventricular valves are part of a complex neural 
mechanism that is involved in the reflex control of the 
heart valves, chordae tendineae and papillary muscle 
during each cardiac cycle (5). In 1989. Kawano et al. 
described neuropeptide Y and calcitonin gene related 
peptide containing nerve fibre degeneration in a 
prolapsed mitral valve cusp (5).
Sympathetic overactivity, usually accompanied by 
reduced parasympathetic activity and heart rate 
variability, is increasingly recognized as a feature in the 
pathogenesis of a number of cardiovascular pathologies 
(40). Cardiac neuronal remodeling accompanies 
hypertension, post-myocardial infarct remodeling 
and heart failure (40). There is association between 
local nerve density and a clinical history of ventricular 
arrhythmia in patients with severe heart failure, and 
it is hypothesed that in some patients myocardial 
injury (myocardial infarction) results in nerve injury, 
followed by nerve sprouting and regional myocardial 
hyperinnervation (18). In patients with end stage 
heart failure due to severe coronary heart disease and 
miocardial infarctions there are found thicker and more 
numerous irregularly distributed nerve fibers in the scar 
tissue than in adjacent normal myocardium (103).
After cardiac transplantation human cardiac allografts 
remain functionally extrinsically denervated, but they 
still appear to contain viable intrinsic nerves (105). The 
relative number of PGP 9.5 immunostained nerves in 
transplanted hearts is less than in innervated (105). 
In patients after cardiac transplantation, reinnervation 
is associated with significantly improved exercise 
performace (18).
Endothelin
In  1988, a 21-amino-acid  vasoconstricting factor 
termed endothelin was isolated from cultured porcine 
aortic endothelial cells (46, 106). Endothelins are 
family of peptides, which comprises endotheli-1 (ET-
1), endothelin-2 (ET-2) and endothelin-3 (ET-3) (4). 
ET-1 is primarily secreted by endothelial cells, but 
it can also be synthesized and released by a variety 
of cell types, such as cardiac myocytes, endocardial 
endothelial cells, intramyocardial capillary endothelial 
cells, kidney, central nervous system (CNS) and 
posterior pituitary (58, 67, 75). Endocardial endothelial 
cells and intramyocardial capillary endothelial cells 
are major source of ET-1 in the normal heart and 
cardiomyocytes are its primary target (67). ET-2 is 
produced in endothelial cells, heart and kidney. ET-3 is 
expressed in endocrine, gastrointestinal and CNS, but 
not in endothelial cells (4, 58, 75). Neonatal rat cardiac 
myocytes express preproET-1 mRNA and synthesize 
and secrete mature ET-1 (109). ET-1 is the predominant 
isoform expressed in the vasculature (4). Intracellular 
ET-1 is produced from inactive big ET-1 via specific 
cleavage by endothelin converting enzyme-1a that 
is expressed in endothelin producing cells (including 
endocardium and myocardium) and extracellular big 
ET-1 is cleaved by endothelin converting enzyme-1b 
at the plasma membrane (4, 109). ET-1 generation 
is increased by many stimuli, including vasoactive 
hormones, growth factors, hypoxia, stress, lipoproteins, 
free radicals, endotoxin and cyclosporin (4). Production 
of ET-1 is inhibited by endothelium derived NO, 
nitrovasodilatators, natriuretic peptides, heparin and 
prostaglandins (4). Cultured endothelial cells secrete 
substantially more ET-1 toward the adjacent vascular 
smooth muscle than into the lumen, therefore 
endothelin is thought to be a locally acting paracrine 
substance rather than a circulating endocrine hormone 
(4).
Endothelins play an important role in cardiac and vascular 
pathology associated with heart failure (109). Plasma 
concentrations of endothelin-1 (ET-1) are increased two 
to three hold in patients with heart failure irrespective 
to aetiology (109). Plasma endothelin levels increase 
significantly (more than fivehold) in few hours after 
uncomplicated myocardial infarction in humans (46, 
91). Increased levels of ET-1 in patients with heart failure 
correlate with patient outcomes and plasma endothelin 
concentrations correlate directly with pulmonary 
artery pressure and pulmonary vascular resistance 
(58). Increased production and biological activity of the 
potent vasoconstrictor and pro-inflammatory peptide 
endothelin is a hallmark of endothelial dysfunction 
(9), while the endothelial dysfunction is associated 
with accelerated progression of heart failure (30). 
Significant amounts of tissue ET-1 is found also in 
active coronary aterosclerotic plaques (107). ET-1 
immunostaining localizes predominantly to areas with 
extensive macrophage infiltration and hypercellular 
regions with evidence for neovascularization - that 
suggests a role of  local inflammatory processes in the 
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production of ET-1 within aterosclerotic lessions (107). 
Endothelin is a potent vasoconstrictor, has inotropic 
and chemotactic properties, and has mitogenic effects 
on smooth muscle cells and fibroblasts, and it stimulates 
synthesis of inflammatory mediators in macrophages 
and fibronectin in smooth muscle cells (32, 46, 56, 58). 
Endothelin has other important effects in the heart, 
including stimulation of myocyte hypertrophy and 
atrial natriuretic peptide secretion from myocytes (61, 
87). The overall action of endothelin is to increase blood 
pressure and vascular tone (4).
Biological activities of ET-1 are mediated mainly 





 and they both are expressed in human atrial and 
myocardial myocytes, atrioventricular conducting 
system, endocardial cells, coronary and pulmonary 
arteries (26, 60, 61, 109). ET
A
-receptors are located in 
vascular smooth muscle, but not in endothelial cells 
(4). ET
B
- receptors are located on endothelial cells (4). 
ET
A
-receptor stimulation by ET-1 cause vascular smooth 
muscle constriction, but ET
B
- receptor activation by 
ET-1 leads to vasodilation via production of NO and 
prostaglandins (4). Some ET
B
- receptors are located 
in vascular smooth muscle where thay may mediate 
vasoconstriction (14). Systemic administration of ET-1 
leads to shortlived decrease (up to few minutes) in 
vascular resistance, followed by the longterm (≥1 hour) 
increase and secondary, probably through increased 
afterload,  decrease cardiac output (4, 46). The initial 
increase in perfusion is caused via nitric oxid and 
prostacyclin release by ET
B
 stimulated endothelial cells 
(46). The decrease in perfusion is primarly mediated by 
ET
A
 on smooth muscle cells. Activation of ET receptors 
lead to an induction of markers of cardiac remodeling, 
including mRNA for troponin I, myosin light chain 2 
and skeletal alpha actin (87).
Endothelin receptor antagonists were developed for the 
treatment of patients with heart failure, but the effect in 
clinical heart failure trials has not been beneficial and 
has led to worsening outcomes in some setting (58, 96). 
Endothelin receptor antagonists have been shown to be 
beneficial in the setting of pulmonary hypertension and 
are currently approved for the treatment of pulmonary 
artery hypertension in patients with moderate disability 
(58).
Vascular Endothelial Growth Factor
Vascular endothelial growth factor (VEGF) is basic, 
heparin-binding, hemodinamic glycoprotein and is also 
known as a vascular permeability factor (29, 28).  It 
is produced by a variety of adult tissues and vascular 
and inflammatory cells (25). VEGF in both physiologic 
and pathologic conditions induces endothelial cell 
migration, proliferation, and sprouting and results in 
angiogenesis and it is essential for embryonic vascular 
dvelopment (25). The location of the VEGF gene is in 
the chromosome 6p21.3 (102). VEGF proteins become 
available to endothelial cells by at least two different 
mechanisms: as freely diffusable proteins and following 
protease activation and cleavage of the longer isoforms 
(28). There are three VEGF related factors - placental 
growth factor (PGF), vascular endothelial growth 
factor B (VEGF-B), Vascular endothelial growth factor 
C (VEGF-C). PGF can potentiate the bioactivity of low 
contentrations of VEGF on endothelial cell growth 
and it has minimal mitogenic activity on endothelial 
cells (71). PGF promotes cardiac hypertrophy (3, 25). 
VEGF-C is found in several human tissues including 
adult heart, it stimulates the growth of human lung 
endothelial cells and induces lymphangiogenesis (25, 
29, 53). VEGF-B distributes primarily in the sceletal 
muscle and myocardium, and is coexpressed with VEGF 
(70). VEGF-B stimulates the growth of human vascular 
endothelial cells  and may participate in the regulation 
of angiogenesis, particularly in muscle (29, 70). Lack of 
VEGF-B leads to characteristic defect (increase in the PQ 
interval in the ECG) in the atrial conduction system in 
mice and may yield to  reduced functional recovery after 
myocardial ischemia (1, 7).
Biological activities of VEGF are mediated mainly 
through two receptors: VEGFR-1 (flt-1) and VEGFR-2 
(flk-1). VEGFR-1  is expressed in a variety of cells 
including endothelial cells, smooth muscle cells, 
monocytes and macrophages, and hematopoietic stem 
cells (25).  It may regulate arteriogenesis, pathological 
angiogenesis, myelomonocyte cell recruitment and lipid 
metabolism (25, 86). VEGFR-2 is mainly expressed 
on vascular endotheliel cells. In adults VEGFR-2 
expression presents only at sites of active angiogenesis 
such as wound healing, tumors, and after myocardial 
inferction (25, 86). In myocardial infarction and sepsis 
VEGFR-2 is a major regulator of vascular permeability 
and cardiac dysfunction (25, 86). VEGFR-2 stimulates 
not only angiogenic signals, but also the secretion of 
various proteins such as the von Willebrand factor from 
endothelial cells (86).
VEGF are major molecules controlling vascular growth 
and function, vascular homeostasis, permeability, and 
vasodilatation (47). It is a potent mitogen for micro and 
macrovascular endohelial cells from arteriae, veins, and 
lyphatics, but it lacks significant mitogenic activity for 
other cell types (29, 28). VEGF is preventing apoptosis 
in vascular endothelial cells by inducing expression of 
the antiapoptotic proteins Bcl-2 and A1 (35).
Myocardial neovascularization is important not only 
for heart development, but also during hypertrophy, 
ischemia and after myocardial infarction (98). VEGF 
mRNA expression in heart is induced by ischemia 
and cyclic stretch of cardiac myocytes and cardiac 
microvascular endothelial cells (28, 108). VEGF is 
critical for angiogenesis in the healing area after 
myocardial infarction - it is promptly expressed in the 
living cardiomyocytes around the infarcted loci and 
in the early stage also in infarcted cardiomyocytes 
(25,  44). Angiogenesis in the lesion begins at 4-5 
hours and continues up to 90 days (25). VEGF has a 
role of enhancing the development of small coronary 
arteries that supply the ischemic myocardium, as well 
as a protective role against myocardial ischemia - 
reperfusion injury (44). VEGF has been shown to be 
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important for neovascularization of the chronically 
ischemic adult heart, it can stimulate collateral vessel 
development in the ischemic myocardium (47, 72). 
There is also evidence of VEGF role in rheumatic 
and degenerative heart valve diseases. In contrast to 
healthy avascular aortic valves, stenotic valves show 
marked neovascularization - small microvessels, 
medium microvessels and organized arterioles (93). 
Neovascularization in the thickened aortic valves can 
suppress disease progression by providing oxygen and 
nutrients to deeper parts of hypertrophied valve leaflet, 
but on the other hand, provoke disease by facilitating 
the transport of inflammatory cells and lipids into the 
leaflets, neovascularization can accelerate valvular 
thickening and calcification (93). Calcification of 
rheumatic cardiac valve tissue and non-rheumatic 
degenerative valve tissue is similar to skeletal bone 
formation and is associated with neoangiogenesis which 
is stimulated by an active inflammatory process and 
the release of VEGF (79, 80). VEGF and it`s receptors 
VEGFR-1 and VEGFR-2 are locally expressed in aortic 
valves and upregulated in stenotic valves (93, 17). VEGF 
and its receptors in stenotic valves are seen preferentially 
in endothelial cells and also to some extent in stromal 
myofibroblasts and histiocytic cells (89, 93). Must cell 
derived tumor necrosis factor α, hypoxic conditions and 
tobacco smoke induces significant increase in VEGF 
secretion by cultured aortic valve myofibroblasts (93).
CONCLUSIONS
Cardiomyocyte apoptosis is an essential process in the 
pathogenesis and progression of heart failure irrespective 
to aetiology, but it can be reduced by appropriate timing 
of surgical intervention and precise choice of pre and 
postoperative medication.  ANUP, ChgA, VEGF and 
ET-1 secretion is a protective response to heart failure 
accordingly it allows to evaluate the preoperative 
condition, effectiveness of treatment and further 
prognosis as well as it may be a therapeutic target.
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